April 11, 2013
The Japan College of Rheumatology has expressed its concerns over the safety of Pfizer Japan’s rheumatoid arthritis (RA) treatment Xeljanz (tofacitinib), warning that the drug might have “an adverse reaction profile that is distinctly different from those of existing biologics.”...read more